Biohaven Research Aktie

Kaufen

Verkaufen

11,40 EUR ±0,00 EUR ±0,00 %

10:10:26

BER

13,50 USD +0,08 USD +0,57 %

nachbörslich01:17:29

BTT

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Bei einem anderen Broker handeln Smartphone

Marktkap.1,17 Mrd. EUR

Div. Rendite0,00%

WKNA3DVH7

ISINVGG1110E1079

SymbolBHVN

Biohaven Research Aktien News

Sortieren:Datum Meistgelesen

22.07.25PR NewswirePomerantz Law Firm Announces the Filing of a Class Action Against Biohaven Ltd. and Certain Officers - BHVN

21.07.25PR NewswireBHVN Investors Have Opportunity to Lead Biohaven Ltd. Securities Fraud Lawsuit with the Schall Law Firm

17.07.25PR NewswireBHVN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biohaven Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

17.07.25PR NewswirePomerantz Law Firm Announces the Filing of a Class Action Against Biohaven Ltd. and Certain Officers - BHVN

17.07.25PR NewswireRosen Law Firm Urges Biohaven Ltd. (NYSE: BHVN) Stockholders to Contact the Firm for Information About Their Rights

22.06.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN

12.06.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN

07.06.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN

01.06.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN

29.05.25PR NewswireBiohaven Enrolls First Patient into Phase 2/3 Trial in Early Parkinson's Disease, Targeting Neuroinflammation with Novel Brain-Penetrant TYK2/JAK1 Inhibitor

28.05.25PR NewswireBiohaven Highlights Innovation and Advancement Across MoDE and TRAP Degrader Platform at R&D Day, Announcing Positive TRAP Degrader Data Achieving > 80% Sustained Reductions in Galactose-Deficient...

28.05.25PR NewswireBiohaven Presents Oncology Program Updates and Preliminary Clinical Data Showcasing Innovative Trop2 and FGFR3 Antibody Drug Conjugates (ADCs) Incorporating Novel TopoIx Payload with Potential to ...

15.05.25PR NewswireFDA Extends PDUFA Date of Biohaven's Troriluzole NDA for Rare Disease Spinocerebellar Ataxia

14.05.25finanzen.netBiohaven Research hat Bilanz für das abgelaufene Quartal gezogen

12.05.25PR NewswireBiohaven Reports First Quarter 2025 Financial Results and Recent Business Developments

28.04.25PR NewswireBiohaven Announces Investment up to $600 Million by Oberland Capital

22.04.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN

08.04.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN

05.04.25PR NewswireBiohaven Presents Data Across Innovative Neuroscience Portfolio at the 2025 American Academy of Neurology (AAN) Annual Meeting

04.04.25finanzen.netMögliche Kaufgelegenheit

Biotech-Aktien unter Druck: Ist der Tiefpunkt bald erreicht?

04.04.25finanzen.netUS-Zölle: China schlägt zurück -- DAX geht massiv tiefer ins Wochenende -- Wall Street stürzt letztlich ab -- Aktien von Rheinmetall, RENK & HENSOLDT im Minus -- Novo Nordisk, Apple im Fokus

31.03.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd - BHVN

17.03.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd - BHVN

05.03.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd - BHVN

04.03.25finanzen.netBiohaven Research stellte Ergebnisse des abgelaufenen Quartals vor

03.03.25PR NewswireBiohaven Reports Positive Degrader Data Achieving > 80% Sustained Reductions in Total IgG with Potential First-in-Class BHV-1300

03.03.25PR NewswireBiohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2024 Financial Results

11.02.25PR NewswireBiohaven Announces FDA Acceptance and Priority Review of Troriluzole New Drug Application for the Treatment of Spinocerebellar Ataxia

13.01.25PR NewswireBiohaven Highlights Portfolio Progress, Innovation, and Anticipated Milestones at the 43rd Annual J.P. Morgan Healthcare Conference; Reports Positive Degrader Data with Rapid, Deep, and Selective ...

07.01.25PR NewswireBiohaven to Present at the 43rd Annual J.P. Morgan Healthcare Conference

16.12.24PR NewswireBiohaven Reports Positive Phase 1 Degrader Data, Achieving Deep Targeted IgG Reductions in the Lowest Subcutaneous Dose Tested; Announces NDA Submission for Troriluzole in SCA and Provides Other K...

06.12.24PR NewswireBiohaven Presents New Data with BHV-7000 Once-Daily Extended-Release Formulation Demonstrating Excellent Safety Profile and Nonclinical Data Updates at American Epilepsy Society 2024 Annual Meeting

25.11.24PR NewswireBiohaven Provides Update on Taldefgrobep Alfa Development Program for Spinal Muscular Atrophy and Obesity

14.11.24finanzen.netBiohaven Research stellte Ergebnisse des abgelaufenen Quartals vor

12.11.24PR NewswireBiohaven Reports Third Quarter 2024 Financial Results and Recent Business Developments

30.09.24PR NewswireBiohaven Initiates Pivotal Trial of Novel Investigational Drug for Treatment of Migraine

23.09.24PR NewswireBiohaven Achieves Positive Topline Results in Pivotal Study of Troriluzole in Spinocerebellar Ataxia (SCA)

21.09.24PR NewswireBiohaven Announces Conference Call to Discuss Topline Pivotal Study Results in Spinocerebellar Ataxia

10.08.24finanzen.netBiohaven Research: Zahlen zum abgelaufenen Jahresviertel

08.08.24PR NewswireBiohaven Reports Second Quarter 2024 Financial Results and Recent Business Developments

Biohaven Research News

Biohaven Research News: auf dieser Seite finden Sie alle Biohaven Research News und Nachrichten zur Biohaven Research Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Biohaven Research News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Biohaven Research News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.